Russian Heart Failure Journal 2004year Efficacy and safety of carvedilol and bisoprolol in the treatment of chronic heart failure in patients with type 2 diabetes mellitus
Efficacy and safety of carvedilol and bisoprolol in the treatment of chronic heart failure in patients with type 2 diabetes mellitus
Gilyarevsk S.R., Stolyarova N.I., Novikova Yu.P., Egorov A.V., Volkova N.S.
Urgency. A possibility of reducing the death rate in patients with chronic heart failure (CHF) and diabetes mellitus (DM) using β-blockers has been demonstrated only for carvedilol. The study was aimed at evaluating efficacy and safety of carvedilol and bisoprolol treatment in patients with CHF and type 2 DM. Materials and methods. It was a randomized, open-label study lasting for 3 months. The study included 40 patients older than 18 years with III-IV functional class (FC) CHF and type 2 DM. The β-blocker treatment was initiated after stabilizing the state of patients. Titration of β-blocker dose was performed by commonly accepted schedules. Functional state, quality of life, left ventricular (LV) global systolic and diastolic function and glucose metabolism were evaluated at baseline and at 3 months. Results. The treatment with carvedilol and bisoprolol did not result in significant changes in fasting and 2-hour postprandial blood glucose or in the level of glycated hemoglobin. The carvedilol treatment was associated with more pronounced improvement of quality of life and more distinct tendency toward improvement of LV diastolic function as compared to the bisoprolol treatment.